Leadership / Management
Mr. Horne has over 12 years of experience in the life science industry as an executive, entrepreneur and investor. He joined Symic Bio as CEO in April 2014. Previously, he was a founding member of TauTona Group, an early stage life science venture capital fund. At TauTona, Mr. Horne founded Aline Aesthetics, a novel biomaterial company, where he led the company as General Manager until its acquisition by Allergan (AGN) in 2014. He also served as Vice President of Business Development for TauTona portfolio companies, which included acquisitions by LifeCell and Novadaq (NVDQ). Mr. Horne has a BS and MS degree from Stanford University in mechanical engineering. He serves on the board of the Bay Area Discovery Museum (non-profit), and is also a Kauffman Fellow.
Rinko Ghosh joined Symic Bio in January 2016. He has 20 years of experience in biotechnology and healthcare. Previously he was Senior Vice President & Chief Business Officer at Nektar Therapeutics. His primary responsibilities at Nektar included business and corporate development, marketing, strategic planning, portfolio evaluation and alliance management. He has been an Advisor to several Life Sciences companies, including Epic Sciences, PulmoKine, MannKind, Pearl Therapeutics (acquired by Astra Zeneca), and Aviron (acquired by MedImmune). Prior to joining Nektar in 2001 he was co-CEO of a biotechnology startup in Asia. Earlier, as a management consultant with A.T. Kearney in San Francisco, and as a scientific consultant with Environ Corp. in Princeton, he worked with multi-national clients in healthcare and other industries. Mr. Ghosh earned his MBA from Wharton, his MS in Engineering from Vanderbilt University, and his BS in Engineering from the IIT, Bombay.
Dr. Bachtell joined Symic Bio in March of 2014 and will be leading clinical research and medical affairs initiatives. Previously, he was the medical as well as global team lead in the osteoarthritis (OA) development program at Genzyme (now part of Sanofi) where he focused on symptomatic and disease modification therapies. During his time in industry Dr. Bachtell worked on biologics, cell therapies as well as medical devices, and led teams in pharmacovigilance, clinical research and medical affairs. His therapeutic focus included general orthopedics, dermatology, immune mediated diseases, and neurology. Prior to industry, he was an attending physician at a teaching hospital as well as an advisor and principal investigator for a biotechnology start up. Dr. Bachtell received his MD from UC San Francisco, completed residency at Oregon Health Sciences University and earned a Masters in Management from Harvard University.
Prior to joining Symic Bio, Ms. Jackson was the CFO of TauTona Group, an early stage life science venture. At TauTona, Ms. Jackson was responsible for the management of all finance and accounting functions, as well as investor communication. She was also closely involved in the sale of TauTona’s assets to Allergan (AGN), LifeCell and Novadaq (NVDQ). Previously, she was the Controller of CV Ingenuity, a medical device company that developed drug-coated balloon platforms, where she assisted in the sale of CV Ingenuity to Covidien (COV). Ms. Jackson started her career at Deloitte and Touche, LLP, where she spent time in both the tax and audit departments.
Dr. Egodage has 20 years of biotherapeutics development experience in the Biotech and Pharma industry both in the US and Europe. He joined Symic Bio as VP of Development and Manufacturing in September 2015 to lead Symic Bio’s biologics programs towards commercialization. Prior to joining Symic Bio, he held leadership positions in Novartis, Eli Lilly, Pharmacia and Monsanto in the areas of biologics research and development, strategy and business development. Dr. Egodage has contributed to numerous IND/IMPD and BLA submissions in multiple therapeutic areas. He led R&D teams for successful collaborations in the areas of cardiovascular and metabolism, oncology and autoimmunity, transplantation and inflammation in his recent biologics strategy and business development role at Novartis. Dr. Egodage received his PhD (Hons) in Bioanalytical Chemistry from The University of Kansas and earned an MBA from the Kellogg School of Management and Otto Beisheim School of Management in Germany.
Ms. Wong-Sarad joined Symic Bio in November 2015 as Vice President, Controller. Ms. Wong-Sarad has 20 years combined experience in biotechnology finance and audit/assurance. Ms. Wong-Sarad previously served as Senior Director, Controller of Hyperion Therapeutics Inc. a commercial pharmaceutical company, and was a key team member responsible for the successful initial public offering and secondary offering of Hyperion. During her time at Hyperion she led finance and accounting function, revenue reporting, SEC reporting and tax, among other responsibilities. Previously, Ms. Wong-Sarad also held various positions in the audit practice of KPMG LLP and Arthur Andersen. Ms. Wong-Sarad is a Certified Public Accountant and holds a Bachelor’s Degree in Accountancy from San Pedro College of Business Administration in the Philippines.
Prior to joining Symic Bio, Dr. Gogas was Senior Director of Preclinical Pharmacology at Nektar Therapeutics where she was responsible for all global preclinical research and development activities. These activities included projects in the areas of oncology, inflammation and pain. Dr. Gogas previously held leadership positions at Xenoport Inc., Neurocrine Biosciences and Roche Pharmaceuticals. Dr. Gogas received her Ph.D. in Pharmacology from Albany Medical College and conducted postdoctoral research at the University of California, San Francisco and Harvard University.
Mr. Anand has many years of experience in the biopharmaceutical industry including responsibility for interactions with international regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mr. Anand has been involved in the development of drugs, biologics, blood products and vaccine therapies for a diverse range of therapeutic areas such as hematology, oncology, CNS, inflammation and orphan disease. Prior to joining Symic Bio, Mr. Anand was Director of Regulatory Affairs at Portola Pharmaceuticals. Mr. Anand has also served in regulatory affairs positions at BioMarin, Vanda, MacuSight and Medimmune. Mr. Anand received a M.S. in Biotechnology from the Johns Hopkins University and a B.S. in Chemistry from Lafayette College.